The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

neurogastrx.com

Founded Year

2012

Stage

Series B - II | Alive

Total Raised

$125M

Last Raised

$60M | 10 mos ago

About Neurogastrx

Neurogastrx is a private biopharmaceutical company focused on developing therapies for gastrointestinal disorders affecting the enteric nervous system.

Neurogastrx Headquarter Location

600 Unicorn Park Drive

Woburn, Massachusetts, 01801,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Neurogastrx

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Neurogastrx is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Neurogastrx Patents

Neurogastrx has filed 8 patents.

The 3 most popular patent topics include:

  • Digestive system
  • Digestive system surgery
  • Gastroenterology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/30/2020

10/19/2021

Cardiac arrhythmia, Piperidines, Antiemetics, Piperazines, Amines

Grant

Application Date

4/30/2020

Grant Date

10/19/2021

Title

Related Topics

Cardiac arrhythmia, Piperidines, Antiemetics, Piperazines, Amines

Status

Grant

Latest Neurogastrx News

Daewoong Pharmaceutical Sees Operating Profits Balloon 5 Times in 2021

Jan 5, 2022

Daewoong Pharmaceutical Sees Operating Profits Balloon 5 Times in 2021 Share Daewoong Pharmaceutical Sees Operating Profits Balloon 5 Times in 2021 By Choi Moon-hee Daewoong Pharmaceutical saw its operating profit in 2021 soar five times from the previous year. Daewoong Pharmaceutical's operating profit in 2021 is estimated to have soared five times from the previous year. The profit growth was driven by increased exports of Nabota and a licensing-out deal for a treatment for gastroesophageal reflux disease. Securities companies estimate Daewoong Pharmaceutical's operating profit for 2021 at about 82.7 billion won, up 4.9 times from 17 billion won a year earlier, according to financial information provider FnGuide. Already, the company’s operating profit in the first three quarters of 2021 stood at about 64 billion won, much larger than the 8.3 billion won in the same period of 2020. Its sales in the Jan.-Nov. period of 2021 increased 7.8 percent from the same period a year ago. Its sales for the whole of 2021 are estimated at 1,121.5 billion won, up 6.2 percent from the previous year. The company licensed out its technology for Fexuprazan, a new drug for gastroesophageal reflux disease, to Neurogastrx in the United States for about 480 billion won in 2021. The deal followed a 380-billion-won licensing-out contract with Shanghai Haini, a subsidiary of China's Yangtze River Pharmaceutical Group, last year. When technology exports to Mexico and Brazil in 2020 are added, Daewoong posted one trillion won in technology exports of Fexuprazan. A certain portion of the technology export income began to be reflected in the company’s business performance, boosting its profits. Sales of Nabota, a botulinum toxin, in 2021 were estimated at about 80 billion won. Nabota's sales in 2020 were around 50 billion won. In other words, sales of Nabota grew by about 60 percent last year. This is due to a significant increase in Nabota exports to the United States. According to the Korea Customs Service, exports of botulinum toxins to the United States between January and November 2021 amounted to about 33.9 billion won, up 91.3 percent from the previous year. Nabota is the only botulinum toxin officially exported to the United States. In other words, Nabota exports to the United States alone inflated by more than 90 percent in 2021. POPULAR

Neurogastrx Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Neurogastrx Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.